Clinical Trials
3
2 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Active, not recruiting
2
66.7%
Completed
1
33.3%
No approval data available
- The cancer pain therapeutics market is expected to experience significant growth by 2034, driven by increasing cancer incidence and the anticipated launch of breakthrough non-opioid therapies. - The United States leads the global market with 2.4 million cancer pain cases in 2023, with nociceptive pain representing the most common pathophysiology type. - Six promising pipeline therapies from companies including InhaleRX, Dogwood Therapeutics, and WinSanTor are positioned to address the critical unmet need for effective non-opioid cancer pain treatments. - Current opioid-dominated treatment approaches face significant limitations including refractory pain cases and safety concerns, creating substantial opportunities for innovative therapeutic mechanisms.
- AlgoTx completed a 276-patient Phase 2 trial evaluating ATX01, a novel topical treatment for chemotherapy-induced peripheral neuropathy, showing encouraging efficacy signals at 15% concentration. - The high-concentration ATX01 demonstrated a clinically relevant 1.6-point reduction in pain on the NPRS scale, though overall results were impacted by significant placebo effects at some study sites. - The non-opioid treatment targeting nociceptive sodium channels showed strong safety profile and promising post-hoc analysis results, supporting further development for addressing the unmet needs of cancer patients.
